Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters


Special Interview with Prof. Arrigo De Benedetti

Published on: 25 Nov 2022 Viewed: 162

On November 18, 2022, the Editorial Office of Cancer Drug Resistance was delighted and honored to have a special interview with Prof. Arrigo De Benedetti from Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, LA, USA.

In the interview, Prof. Arrigo De Benedetti summarized the main content and talked about the significance of his article "Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance" (Full article link: published in Cancer Drug Resistance in 2021.

He elaborated in more detail on a new study in his lab on a phenothiazine analog named J54, which has higher efficacy in TLK1 inhibition and lower non-target effects than Thioridazine.

Moreover, Prof. Arrigo De Benedetti pointed out the hotspots in mCRPC and drug resistance research over the next few years, mainly focusing on DNA damage response and repair passways.

Lastly, he shared his team's recent research progress. They have begun investigating the new function of TLK1 as a crucial upstream activator for MK5, a central kinase involved in cell motility/invasion/ metastasis. This is a departure from the classic view of TLK1 as a kinase mainly involved in chromatin dynamics.

Introduction of Prof. Arrigo De Benedetti

Prof. Arrigo De Benedetti is an academic researcher from Department of Biochemistry and Molecular Biology at Louisiana State University Health Sciences Center, USA. His research interest mainly focuses on DNA Damage and Repair. Currently, his team is focusing on the function of TLK1 in Homologous Recombination Repair based on its regulation of Rad54, the key DNA motor of recombinational repair. He has authored or co-authored over 60 publications with 3,183 citations.

Respectfully Submitted by the Journal Editorial Office
Cancer Drug Resistance

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties